Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLB101 vs Blinatumomab in Adult Relapsed/Refractory CD19-Positive B-ALL (Phase I/III)
ChiCTR2600122746Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of BLB-101 in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Steady-state concentration (Css), AUC0-24 on Day 1 (AUC0-24,d1) and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
BLB-101
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2600122746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122746.